Background: Melasma and post-inflammatory hyperpigmentation provide a significant source of\npsychosocial morbidity, especially in those with Fitzpatrick skin types III-VI. In Europe, a proprietary\nproduct aimed at treating these conditions, similar to Kligman�s formula but with a longer expiry\ndate, has become available. Objectives: To assess patient satisfaction with a newly available\ncombination de-pigmenting preparation. Methods: We conducted a small study to see if patients\nfelt that this new product affected their quality of life and skin symptoms from hyperpigmentation.\n41 subjects, who had all been prescribed a 15 g tube to use sparingly at night for 90 days within\nthe last 12 months were telephoned to rate the effect the cream had on their quality of life and\nskin symptom improvement. Each patient also had their Dermatology Life Quality Index (DLQI)\nscore assessed. Results: Out of the 29 patients who responded to the study, 22 had melasma and 7\nhad post-inflammatory hyperpigmentation from acne. 21 subjects felt that the cream made either\na marked or moderate improvement on their quality of life and 23 subjects felt that the cream\nmade either a marked or moderate improvement on their skin symptoms. Conclusion: Patients\nreported improvement in both hyperpigmentation and quality of life, suggesting a high level of satisfaction\nwith treatment. The long shelf life of the product may also promote compliance and reduce\nhealth- care costs.
Loading....